Drug interactions of lithium and other antimanic/mood-stabilizing medications

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 5, 2003, Pages 38-43

  Dunner, David L ^a  

^a Center for Anxiety and Depression   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID; AMILORIDE; AMINOPHYLLINE; CAFFEINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GABAPENTIN; LAMOTRIGINE; LITHIUM; MANNITOL; MOOD STABILIZER; NONSTEROID ANTIINFLAMMATORY AGENT; OXCARBAZEPINE; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; TOPIRAMATE; TRANQUILIZER; UNCLASSIFIED DRUG; VALPROIC ACID;

ACNE; ARTICLE; ATAXIA; BIPOLAR DISORDER; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIARRHEA; DIURESIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRY SKIN; EBSTEIN ANOMALY; EDEMA; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; FASCICULATION; FATIGUE; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEART ARRHYTHMIA; HUMAN; HYPOTHYROIDISM; KIDNEY DISEASE; KIDNEY FAILURE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MANIA; MUSCLE HYPOTONIA; MUSCLE WEAKNESS; NAUSEA; NEPHROGENIC DIABETES INSIPIDUS; NEUROLOGIC DISEASE; NEUROTOXICITY; POLYURIA; PRIORITY JOURNAL; PSORIASIS; RAPID CYCLING BIPOLAR DISORDER; RECURRENT DISEASE; SEDATION; SEIZURE; SIDE EFFECT; SINUS NODE DISEASE; SKIN DISEASE; SLOW RELEASE FORMULATION; SLURRED SPEECH; TERATOGENICITY; TREMOR; VOMITING; WEIGHT GAIN;

ANTICONVULSANTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; DRUG INTERACTIONS; HUMANS; LITHIUM; VALPROIC ACID;

EID: 0038642180     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Dunner DL. Optimizing lithium treatment. J Clin Psychiatry 2000;61 (suppl 9):76-81
2. Mitchell JE, Mackenzie TB. Cardiac effects of lithium therapy in man: a review. J Clin Psychiatry 1982;43:41-51
3. Gitlin MJ, Cochran SD, Jamison KR. Maintenance lithium treatment: side effects and compliance. J Clin Psychiatry 1989;50:127-131
4. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis: recognition and management. Am J Clin Dermatol 2000;1:159-165
5. Chan HH, Wing Y, Su R, et al. A control study of the cutaneous side effects of chronic lithium therapy. J Affect Disord 2000;57:107-113
6. Gupta AK, Knowles SR, Gupta MA, et al. Lithium therapy associated with hidradenitis suppurativa: a case report and a review of the dermatologic side effects of lithium. J Am Acad Dermatol 1995;32:382-386
7. Vestergaard P, Amdisen A, Schou M. Clinically significant side effects of lithium treatment: a survey of 237 patients in long-term treatment. Acta Psychiatr Scand 1980;62:193-200
8. Stancer HC, Kivi R. Lithium carbonate and oedema. Lancet 1971;2:985
9. Jefferson JW. Lithium: the present and the future. J Clin Psychiatry 1990;51 (suppl 8):4-8
10. Myers DH, Carter RA, Burns BH, et al. A prospective study of the effects of lithium on thyroid function and on the prevalence of antithyroid antibodies. Psychol Med 1985;15:55-61
11. Kallen B, Tandberg A. Lithium and pregnancy: a cohort study on manicdepressive women. Acta Psychiatr Scand 1983;68:134-139
12. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994;271:146-150
13. Rane A, Tomson G, Bjarke B. Effects of maternal lithium therapy in a newborn infant. J Pediatr 1978;93:296-297
14. Ghadirian AM, Lehman HE. Neurological side effects of lithium: organic brain syndrome, seizures, extrapyramidal side effects, and EEG changes. Compr Psychiatry 1980;21:327-335
15. Gitlin MJ. Lithium-induced renal insufficiency. J Clin Psychopharmacol 1993;13:276-279
16. Chen Y, Silverstone T. Lithium and weight gain. Int Clin Psychopharmacol 1990;5:217-225
17. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996;153:993-1000
18. Dempsey M, Dunner DL, Fieve RR, et al. Treatment of excessive weight gain in patients taking lithium. Am J Psychiatry 1976;133:1082-1084
19. Bone S, Roose SP, Dunner DL, et al. Incidence of side effects in patients on long-term lithium treatment. Am J Psychiatry 1980;137:103-104
20. Eskalith (lithium carbonate). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2002:1527-1528
21. Lithobid (lithium carbonate). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2002:3255-3256
22. Jefferson JW, Greist JH, Baudhuin M. Lithium: interactions with other drugs. J Clin Psychopharmacol 1981;1:124-134
23. Chaudhry RP, Waters BG. Lithium and carbamazepine interaction: possible neurotoxicity. J Clin Psychiatry 1983;44:30-31
24. Weinrauch LA, Belock S, D'Elia JA. Decreased serum lithium during verapamil therapy. Am Heart J 1984;108:1378-1380
25. Fieve RR, Peselow ED. Lithium toxicity. In: Bach RO, ed. Lithium: Current Applications in Science, Medicine, and Technology. New York, NY: John Wiley and Sons; 1985:353-375
26. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Bipolar Disorder. Am J Psychiatry 1994;151:1-36
27. Perlis RH, Sachs GS, Lafer B, et al. Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data. Am J Psychiatry 2002;159:1155-1159
28. Solomon DA, Ristow WR, Keller MB, et al. Serum lithium levels and psychosocial function in patients with bipolar I disorder. Am J Psychiatry 1996;153:1301-1307
29. Hopkins HS, Gelenberg AJ. Serum lithium levels and the outcome of maintenance therapy of bipolar disorder. Bipolar Disord 2000;2(3 pt 1):174-179
30. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of out-patients with bipolar I disorder. Arch Gen Psychiatry 2000;57:481-489
31. Depacon (valproate sodium). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2002:416-421
32. Depakene (valproic acid). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2002:421-426
33. Depakote (divalproex sodium). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2002:430-436
34. Bryant AE III, Dreifuss FE. Valproic acid hepatic fatalities, III: US experience since 1986. Neurology 1996;46:465-469
35. Nau H. Valproic acid-induced neural tube defects. Ciba Found Symp 1994;181:144-152
36. Asconapé JJ, Penry JK, Dreifuss FE, et al. Valproate-associated pancreatitis. Epilepsia 1993;34:177-183
37. Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001;57:445-449
38. Pavlakis SG, Chusid RL, Roye DP, et al. Valproate therapy: predisposition to bone fracture? Pediatr Neurol 1998;19:143-144
39. Zeller JA, Schlesinger S, Runge U, et al. Influence of valproate monotherapy on platelet activation and hematologic values. Epilepsia 1999;40:186-189
40. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyper-androgenism in women taking valproate for epilepsy. N Engl J Med 1993; 329:1383-1388
41. Morrell MJ. Epilepsy in women: the science of why it is special. Neurology 1999;4(suppl 1):S42-S48
42. Tegretol (carbamazepine). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2002:2404-2407
43. Carbatrol (carbamazepine). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2002:3234-3236
44. Trileptal (oxcarbazepine). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2002:2407-2412
45. Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and history of mania. Am J Psychiatry 1999; 156:1164-1169
46. Pande AC, Crockatt JG, Janney CA, et al, for the Gabapentin Bipolar Disorder Study Group. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Disord 2000;2:249-255
47. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607-614
48. Yatham LN, Kusumakar V, Calabrese JR, et al. Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. J Clin Psychiatry 2002;63:275-283
49. Neurontin (gabapentin). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2002:2655-2659
50. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999;60:79-88
51. Calabrese JR, Bowden CL, DeVeaugh-Geiss J, et al. Lamotrigine demonstrates long-term mood stabilization in manic patients. In: New Research Abstracts of the 154th Annual Meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, La; Abstract NR403:110
52. Calabrese JR, Suppes T, Bowden CL, et al, for the Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000;61:841-850
53. Messenheimer JA. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci 1998;25:S14-S18
54. Normann C, Langosch J, Schaerer LO, et al. Treatment of acute mania with topiramate [letter]. Am J Psychiatry 1999;156:968-969
55. Hussain M. Treatment of bipolar depression with topiramate. Presented at the 38th annual meeting of the American College of Neuropsychopharmacology; Dec 12-16, 1999; Acapulco, Mexico
56. Calabrese JR. Topiramate versus placebo in mania. Presented at the 153rd annual meeting of the American Psychiatric Association; May 13-18, 2000; Chicago, III
57. Naguib M, Koom R. Interactions between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management. CNS Drugs 2002;16:229-247
58. Goodnick PJ, Rush AJ, George MS. Vagus nerve stimulation in depression. Expert Opin Pharmacother 2001;2:1061-1063
59. Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of out-come. Neuropsychopharmacology 2001;25:713-728